文献速递白血病

维奈克拉联合低甲基化药物用于FLT3突变急性髓系白血病

Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2020-07-28

该回顾性研究分析了50例FLT3突变急性髓系白血病(AML)患者(17例初治、33例复发/难治)接受维奈克拉(VEN)联合低甲基化药物(HMA)治疗的结局。总体完全缓解/完全缓解伴血细胞计数不完全恢复(CR/CRi)率为60%(初治AML为94%,复发/难治AML为42%),早期(60天)治疗相关死亡率为2%。复发/难治状态是较低完全缓解的独立预测因素(OR:0.08;95%CI:0.00-0.60,P=0.03)。

要点

  • VEN-HMA在FLT3突变AML中总体CR/CRi率为60%,初治患者为94%,复发/难治患者为42%。
  • 复发/难治状态是较低完全缓解的独立预测因素(OR:0.08;95%CI:0.00-0.60,P=0.03)。
  • 早期(60天)治疗相关死亡率为2%。

核心结论

  • VEN-HMA在初治不适合强化疗及复发/难治的FLT3突变AML患者中均显示出令人鼓舞的疗效。

研究设计与样本

  • 回顾性分析50例FLT3突变AML患者(17例初治,33例复发/难治)接受维奈克拉联合低甲基化药物治疗的结局。

主要发现

  • 总体CR/CRi率为60%(初治AML为94%,复发/难治AML为42%)。
  • 早期(60天)治疗相关死亡率为2%。
  • 复发/难治状态是较低完全缓解的独立预测因素(OR:0.08;95%CI:0.00-0.60,P=0.03)。
  • 细胞遗传学-分子风险、共存突变、FLT3突变类型(ITD vs TKD)、ITD等位基因比值、HMA类型、年龄、既往HMA暴露及既往接受异基因移植均未独立影响缓解或白血病无病生存(LFS)。
  • 共存IDH突变与较低CR/CRi相关(P=0.01),ASXL1或TET2突变显示与较高CR/CRi的非显著关联(两者P=0.07)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FMS-like tyrosine kinase 3 (FLT3) mutations are prevalent in acute myeloid leukemia (AML), and their presence confers adverse risk. FLT3-mutated (FLT3m) AML is a challenging leukemia to manage, particularly in older and unfit patients as well as patients with relapsed/refractory (r/r) disease. We retrospectively analyzed the outcomes of 50 FLT3m AML patients (17 treatment-naïve, 33 r/r) treated with venetoclax (VEN) and hypomethylating agents (HMA). The overall CR/CRi rate with VEN-HMA was 60% (94% in treatment-naïve AML and 42% in r/r AML). Early (60-days) treatment related mortality was 2%. The r/r AML setting was an independent predictor of lower complete response (OR: 0.08; 95%CI: 0.00-0.60, P = .03). Cytogenetics-molecular risk, concurrent mutations, the type of FLT3 mutation (ITD vs TKD), the ITD allelic ratio, the type of HMA, age, prior exposure to HMA and receipt of prior allogeneic transplant did not independently impact response or leukemia-free survival (LFS). Concurrent IDH mutations were associated with lower CR/CRi (P = .01), while ASXL1 or TET2 mutations showed a non-significant association toward higher CR/CRi (P = .07, for both). However, none of the concurrent mutations were an independent predictor for response when adjusted to AML setting. In conclusion, VEN-HMA is associated with encouraging efficacy in FLT3m AML among both newly diagnosed unfit and r/r patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Aldoss I, Zhang J, Mei M, et al. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. 2020. PMID: 32628327. doi:10.1002/ajh.25929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。